ΔN133p53 expression levels in relation to haplotypes of the TP53 internal promoter region

Human Mutation

Volumn 31, Issue 4, 2010, Pages 456-465

  Bellini, Ilaria ^a   Pitto, Letizia ^b   Marini, Maria G ^c   Porcu, Loredana ^d   Moi, Paolo ^d   Garritano, Sonia ^e   Boldrini, Laura ^a   Rainaldi, Giuseppe ^b   Fontanini, Gabriella ^a   Chiarugi, Massimo ^a   Barale, Roberto ^a   Gemignani, Federica ^a   Landi, Stefano ^a  

^a UNIVERSITY OF PISA   (Italy)

^b INSTITUTE OF CLINICAL PHYSIOLOGY   (Italy)

^c CNR   (Italy)

^d UNIVERSITY OF CAGLIARI   (Italy)

^e UNIVERSITY OF GENOA   (Italy)

Author keywords

N133p53; Internal promoter region; IPR; TP53

Indexed keywords

CAMPTOTHECIN; PROTEIN P53; DNA; ISOPROTEIN; LUCIFERASE; MUTANT PROTEIN;

ARTICLE; CELL STRAIN HEK293; CONCENTRATION RESPONSE; CONTROLLED STUDY; GENE ACTIVITY; GENE CONTROL; GENE EXPRESSION; HAPLOTYPE; HELA CELL; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROMOTER REGION; SINGLE NUCLEOTIDE POLYMORPHISM; BIOLOGY; GEL MOBILITY SHIFT ASSAY; GENETICS; HOMOZYGOTE; INTRON; METABOLISM; POLYMERASE CHAIN REACTION; PROTEIN BINDING;

COMPUTATIONAL BIOLOGY; DNA; ELECTROPHORETIC MOBILITY SHIFT ASSAY; HAPLOTYPES; HELA CELLS; HOMOZYGOTE; HUMANS; INTRONS; LUCIFERASES; MUTANT PROTEINS; POLYMERASE CHAIN REACTION; PROMOTER REGIONS, GENETIC; PROTEIN BINDING; PROTEIN ISOFORMS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 77950422784     PISSN: 10597794     EISSN: 10981004     Source Type: Journal    
DOI: 10.1002/humu.21214     Document Type: Article

References (74)

1. Andrews NC, Faller DV. 1991. A rapid micropreparation technique for extraction of DNA-binding proteins from limiting numbers of mammalian cells. Nucleic Acids Res 19:2499.
2. Anensen N, Oyan AM, Bourdon JC, Kalland KH, Bruserud O, Gjertsen BT. 2006. A distinct p53 protein isoform signature reflects the onset of induction chemotherapy for acute myeloid leukemia. Clin Cancer Res 12:3985-3992.
3. Boldrup L, Bourdon JC, Coates PJ, Sjostrom B, Nylander K. 2007. Expression of p53 isoforms in squamous cell carcinoma of the head and neck. Eur J Cancer 43:617-623.
4. Bourdon JC. 2007a. p53 and its isoforms in cancer. Br J Cancer 97:277-282.
5. Bourdon JC. 2007b. p53 Family isoforms. Curr Pharm Biotechnol 8:332-336.
6. Bourdon JC, Fernandes K, Murray-Zmijewski F, Liu G, Diot A, Xirodimas DP, Saville MK, Lane DP. 2005. p53 isoforms can regulate p53 transcriptional activity. Genes Dev 19:2122-2137.
7. Bourdon JC, guin-Chambon V, Lelong JC, Dessen P, May P, Debuire B, May E. 1997. Further characterisation of the p53 responsive element - identification of new candidate genes for trans-activation by p53. Oncogene 14:85-94.
8. Buyru N, Altinisik J, Demokan S, Dalay N. 2007. p53 genotypes and haplotypes associated with risk of breast cancer. Cancer Detect Prev 31:207-213.
9. Cartharius K, Frech K, Grote K, Klocke B, Haltmeier M, Klingenhoff A, Frisch M, Bayerlein M, Werner T. 2005. MatInspector and beyond: promoter analysis based on transcription factor binding sites. Bioinformatics 21:2933-2942.
10. Cenci M, French D, Pisani T, Alderisio M, Lombardi AM, Marchese R, Colelli F, Vecchione A. 2003. p53 polymorphism at codon 72 is not a risk factor for cervical carcinogenesis in central Italy. Anticancer Res 23:1385-1387.
11. Chan WM, Poon RY. 2007. The p53 Isoform Deltap53 lacks intrinsic transcriptional activity and reveals the critical role of nuclear import in dominant-negative activity. Cancer Res 67:1959-1969.
12. Chen J, Ng SM, Chang C, Zhang Z, Bourdon JC, Lane DP, Peng J. 2009. p53 isoform delta113p53 is a p53 target gene that antagonizes p53 apoptotic activity via BclxL activation in zebrafish. Genes Dev 23:278-290.
13. Comar M, Molin GD, Guaschino S, Campello C. 2004. p53 at codon 72 polymorphism, human papillomavirus infection and cervical lesions: a cross-sectional study from northeastern Italy. Eur J Obstet Gynecol Reprod Biol 114:210-214.
14. Costa S, Pinto D, Pereira D, Rodrigues H, Cameselle-Teijeiro J, Medeiros R, Schmitt F. 2008. Importance of TP53 codon 72 and intron 3 duplication 16bp polymorphisms in prediction of susceptibility on breast cancer. BMC Cancer 8:32.
15. Dumont P, Leu JI, Della III PA, George DL, Murphy M. 2003. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 33:357-365.
16. El-Deiry WS, Kern SE, Pietenpol JA, Kinzler KW, Vogelstein B. 1992. Definition of a consensus binding site for p53. Nat Genet 1:45-49.
17. Ezzikouri S, El Feydi AE, Chafik A, Benazzouz M, El KL, Afifi R, Hassar M, Pineau P, Benjelloun S. 2007. The Pro variant of the p53 codon 72 polymorphism is associated with hepatocellular carcinoma in Moroccan population. Hepatol Res 37:748-754.
18. Fan R, Wu MT, Miller D, Wain JC, Kelsey KT, Wiencke JK, Christiani DC. 2000. The p53 codon 72 polymorphism and lung cancer risk. Cancer Epidemiol Biomarkers Prev 9:1037-1042.
19. Flaman JM, Waridel F, Estreicher A, Vannier A, Limacher JM, Gilbert D, Iggo R, Frebourg T. 1996. The human tumour suppressor gene p53 is alternatively spliced in normal cells. Oncogene 12:813-818.
20. Fried M, Crothers DM. 1981. Equilibria and kinetics of lac repressor-operator interactions by polyacrylamide gel electrophoresis. Nucleic Acids Res 9:6505-6525.
21. Gemignani F, Moreno V, Landi S, Moullan N, Chabrier A, Gutierrez-Enriquez S, Hall J, Guino E, Peinado MA, Capella G, Canzian F. 2004. A TP53 polymorphism is associated with increased risk of colorectal cancer and with reduced levels of TP53 mRNA. Oncogene 23:1954-1956.
22. Ghosh A, Stewart D, Matlashewski G. 2004. Regulation of human p53 activity and cell localization by alternative splicing. Mol Cell Biol 24:7987-7997.
23. Granja F, Morari J, Morari EC, Correa LA, Assumpcao LV, Ward LS. 2004. Proline homozygosity in codon 72 of p53 is a factor of susceptibility for thyroid cancer. Cancer Lett 210:151-157.
24. Hainaut P. 1995. The tumor suppressor protein p53: a receptor to genotoxic stress that controls cell growth and survival. Curr Opin Oncol 7:76-82.
25. Hainaut P, Hernandez T, Robinson A, Rodriguez-Tome P, Flores T, Hollstein M, Harris CC, Montesano R. 1998. IARC Database of p53 gene mutations in human tumors and cell lines: updated compilation, revised formats and new visualisation tools. Nucleic Acids Res 26:205-213.
26. Hainaut P, Hollstein M. 2000. p53 and human cancer: the first ten thousand mutations. Adv Cancer Res 77:81-137.
27. Hainaut P, Soussi T, Shomer B, Hollstein M, Greenblatt M, Hovig E, Harris CC, Montesano R. 1997. Database of p53 gene somatic mutations in human tumors and cell lines: updated compilation and future prospects. Nucleic Acids Res 25:151-157.
28. Harris SL, Gil G, Robins H, Hu W, Hirshfield K, Bond E, Bond G, Levine AJ. 2005. Detection of functional single-nucleotide polymorphisms that affect apoptosis. Proc Natl Acad Sci USA 102:16297-16302.
29. Harris SL, Levine AJ. 2005. The p53 pathway: positive and negative feedback loops. Oncogene 24:2899-2908.
30. Hernandez-Boussard T, Rodriguez-Tome P, Montesano R, Hainaut P. 1999. IARC p53 mutation database: a relational database to compile and analyze p53 mutations in human tumors and cell lines. International Agency for Research on Cancer. Hum Mutat 14:1-8.
31. Hollstein M, Shomer B, Greenblatt M, Soussi T, Hovig E, Montesano R, Harris CC. 1996. Somatic point mutations in the p53 gene of human tumors and cell lines: updated compilation. Nucleic Acids Res 24:141-146.
32. Hollstein M, Sidransky D, Vogelstein B, Harris CC. 1991. p53 mutations in human cancers. Science 253:49-53.
33. Hollstein M, Soussi T, Thomas G, von Brevern MC, Bartsch. 1997. P53 gene alterations in human tumors: perspectives for cancer control. Recent Results Cancer Res 143:369-389.
34. Huang SP, Wu WJ, Chang WS, Wu MT, Chen YY, Chen YJ, Yu CC, Wu TT, Lee YH, Huang JK, Huang CH. 2004. p53 Codon 72 and p21 codon 31 polymorphisms in prostate cancer. Cancer Epidemiol Biomarkers Prev 13:2217-2224.
35. Huang XE, Hamajima N, Katsuda N, Matsuo K, Hirose K, Mizutani M, Iwata H, Miura S, Xiang J, Tokudome S, Tajima K. 2003. Association of p53 codon Arg72Pro and p73 G4C14-to-A4T14 at exon 2 genetic polymorphisms with the risk of Japanese breast cancer. Breast Cancer 10:307-311.
36. Hung RJ, Baragatti M, Thomas D, McKay J, Szeszenia-Dabrowska N, Zaridze D, Lissowska J, Rudnai P, Fabianova E, Mates D, Foretova L, Janout V, Bencko V, Chabrier A, Moullan N, Canzian F, Hall J, Boffetta P, Brennan P. 2007. Inherited predisposition of lung cancer: a hierarchical modeling approach to DNA repair and cell cycle control pathways. Cancer Epidemiol Biomarkers Prev 16:2736-2744.
37. Kietthubthew S, Sriplung H, Au WW, Ishida T. 2003. The p53 codon 72 polymorphism and risk of oral cancer in Southern Thailand. Asian Pac J Cancer Prev 4:209-214.
38. Kim JM, Lee OY, Lee CG, Kwon SJ, Kim KS, Moon W, Koh DH, Lee HL, Yoon BC, Choi HS, Hahm JS, Lee MH, Lee DH. 2007. [p53 Codon 72 and 16-bp duplication polymorphisms of gastric cancer in Koreans]. Korean J Gastroenterol 50:292-298.
39. Ko LJ, Prives C. 1996. p53: puzzle and paradigm. Genes Dev 10:1054-1072.
40. Koushik A, Platt RW, Franco EL. 2004. p53 codon 72 polymorphism and cervical neoplasia: a meta-analysis review. Cancer Epidemiol Biomarkers Prev 13:11-22.
41. Lane DP. 1992. Cancer. p53, guardian of the genome. Nature 358:15-16.
42. Levine AJ. 1997. p53, the cellular gatekeeper for growth and division. Cell 88:323-331.
43. Li CY, Liu JH, Huang BJ. 2004. [Correlation between P53 codon 72 polymorphism and tumorigenesis of cervical cancer]. Ai Zheng 23:1396-1399.
44. Makni H, Franco EL, Kaiano J, Villa LL, Labrecque S, Dudley R, Storey A, Matlashewski G. 2000. P53 polymorphism in codon 72 and risk of human papillomavirus-induced cervical cancer: effect of inter-laboratory variation. Int J Cancer 87:528-533.
45. Marcel V, Hainaut P. 2009. p53 isoforms-a conspiracy to kidnap p53 tumor suppressor activity? Cell Mol Life Sci 66:391-406.
46. Miller DP, Liu G, De V, I, Lynch TJ, Wain JC, Su L, Christiani DC. 2002. Combinations of the variant genotypes of GSTP1, GSTM1, and p53 are associated with an increased lung cancer risk. Cancer Res 62:2819-2823.
47. Mitra S, Chatterjee S, Panda CK, Chaudhuri K, Ray K, Bhattacharyya NP, Sengupta A, Roychoudhury S. 2003. Haplotype structure of TP53 locus in Indian population and possible association with head and neck cancer. Ann Hum Genet 67:26-34.
48. Mitra S, Misra C, Singh RK, Panda CK, Roychoudhury S. 2005. Association of specific genotype and haplotype of p53 gene with cervical cancer in India. J Clin Pathol 58:26-31.
49. Nan H, Qureshi AA, Hunter DJ, Han J. 2008. Interaction between p53 codon 72 polymorphism and melanocortin 1 receptor variants on suntan response and cutaneous melanoma risk. Br J Dermatol 159:314-321.
50. Olivier M, Goldgar DE, Sodha N, Ohgaki H, Kleihues P, Hainaut P, Eeles RA. 2003. Li-Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype. Cancer Res 63:6643-6650.
51. Pastinen T, Hudson TJ. 2004. Cis-acting regulatory variation in the human genome. Science 306:647-650.
52. Perez LO, Abba MC, Dulout FN, Golijow CD. 2006. Evaluation of p53 codon 72 polymorphism in adenocarcinomas of the colon and rectum in La Plata, Argentina. World J Gastroenterol 12:1426-1429.
53. Pietsch EC, Humbey O, Murphy ME. 2006. Polymorphisms in the p53 pathway. Oncogene 25:1602-1611.
54. Pim D, Banks L. 2004. p53 polymorphic variants at codon 72 exert different effects on cell cycle progression. Int J Cancer 108:196-199.
55. Ray PS, Grover R, Das S. 2006. Two internal ribosome entry sites mediate the translation of p53 isoforms. EMBO Rep 7:404-410.
56. rbel-Alon S, Menczer J, Feldman N, Glezerman M, Yeremin L, Friedman E. 2002. Codon 72 polymorphism of p53 in Israeli Jewish cervical cancer patients and healthy women. Int J Gynecol Cancer 12:741-744.
57. Scheet P, Stephens M. 2006. A fast and flexible statistical model for large-scale population genotype data: applications to inferring missing genotypes and haplotypic phase. Am J Hum Genet 78:629-644.
58. Shen H, Zheng Y, Sturgis EM, Spitz MR, Wei Q. 2002. P53 codon 72 polymorphism and risk of squamous cell carcinoma of the head and neck: a case-control study. Cancer Lett 183:123-130.
59. Shiio Y, Yamamoto T, Yamaguchi N. 1993. Identification of a DNA element that can enhance p53-mediated transactivation. Oncogene 8:2059-2065.
60. Siddique M, Sabapathy K. 2006. Trp53-dependent DNA-repair is affected by the codon 72 polymorphism. Oncogene 25:3489-3500.
61. Sotamaa K, Liyanarachchi S, Mecklin JP, Jarvinen H, Aaltonen LA, Peltomaki P, de la Chapelle. 2005. p53 codon 72 and MDM2 SNP309 polymorphisms and age of colorectal cancer onset in Lynch syndrome. Clin Cancer Res 11:6840-6844.
62. Soulitzis N, Sourvinos G, Dokianakis DN, Spandidos DA. 2002. p53 codon 72 polymorphism and its association with bladder cancer. Cancer Lett 179:175-183.
63. Stamatoyannopoulos JA. 2004. The genomics of gene expression. Genomics 84:449-457.
64. Starinsky S, Figer A, Ben-Asher E, Geva R, Flex D, Fidder HH, Zidan J, Lancet D, Friedman E. 2005. Genotype phenotype correlations in Israeli colorectal cancer patients. Int J Cancer 114:58-73.
65. Steele RJ, Thompson AM, Hall PA, Lane DP. 1998. The p53 tumour suppressor gene. Br J Surg 85:1460-1467.
66. Szymanowska A, Jassem E, Dziadziuszko R, Borg A, Limon J, Kobierska-Gulida G, Rzyman W, Jassem J. 2006. Increased risk of non-small cell lung cancer and frequency of somatic TP53 gene mutations in Pro72 carriers of TP53 Arg72Pro polymorphism. Lung Cancer 52:9-14.
67. Tachezy R, Mikyskova I, Salakova M, Van RM. 1999. Correlation between human papillomavirus-associated cervical cancer and p53 codon 72 arginine/proline polymorphism. Hum Genet 105:564-566.
68. teenyi-Agaba C, Dai M, Le CF, Katongole-Mbidde E, Smet A, Tommasino M, Franceschi S, Hainaut P, Weiderpass E. 2004. TP53 mutations in squamous-cell carcinomas of the conjunctiva: evidence for UV-induced mutagenesis. Mutagenesis 19:399-401.
69. Terry CF, Loukaci V, Green FR. 2000. Cooperative influence of genetic polymorphisms on interleukin 6 transcriptional regulation. J Biol Chem 275:18138-18144.
70. Tiwawech D, Srivatanakul P, Karaluk A, Ishida T. 2003. The p53 codon 72 polymorphism in Thai nasopharyngeal carcinoma. Cancer Lett 198:69-75.
71. Twu CW, Jiang RS, Shu CH, Lin JC. 2006. Association of p53 codon 72 polymorphism with risk of hypopharyngeal squamous cell carcinoma in Taiwan. J Formos Med Assoc 105:99-104.
72. Whibley C, Pharoah PD, Hollstein M. 2009. p53 polymorphisms: cancer implications. Nat Rev Cancer 9:95-107.
73. Yang YC, Chang CL, Chen ML. 2001. Effect of p53 polymorphism on the susceptibility of cervical cancer. Gynecol Obstet Invest 51:197-201.
74. Zhou Y, Li N, Zhuang W, Liu GJ, Wu TX, Yao X, Du L, Wei ML, Wu XT. 2007. P53 codon 72 polymorphism and gastric cancer: a meta-analysis of the literature. Int J Cancer 121:1481-1486.